ClinicalTrials.gg
Status unknownNCT01210768Updated Nov 23, 2021

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

A Phase 2 interventional study of Epirubicin+Cyclophosphamide and liposomal-doxorubicin+Cyclophosphamide in Breast Cancer, sponsored by TTY Biopharm. Status unknown at 9 sites in Taiwan. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-23.

Sponsored by TTY Biopharm · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Planned enrollment
9th of 66
254 · median 57
Started
2010
with 1 other
Phase 2
37 of 67
2 open now
Registered
36th of 67
by date

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 9th largest by planned enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2010, is one of 37 in phase 2, and was the 36th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

Primary objective:

  • To evaluate the disease-free survival (DFS) in the two randomized arms after therapy with LC vs. EC in chemo-naive Her2-patients with stage I or II breast cancer

Secondary objectives:

  • To assess the overall survival (OS)
  • To establish the safety profile by assessing the toxicities and tolerability
  • To assess the quality of life (QoL)
  • To evaluate survival correlation with biomarkers expression.
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Phase II
  • Pegylated Liposomal Doxorubicin
  • Adjuvant Chemotherapy
  • Breast Cancer
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive, but non-inflammatory, breast adenocarcinoma with stage I or II (if N0, T must be >1cm) disease
  • Her2-negative on fluorescence in situ hybridization (FISH) study
  • performance status of 0, 1
  • female, age between 20 and 70 years
  • of at least one year
  • ability to understand and willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Her2 3+ over-expression on immunohistochemistry (IHC), or Her2 amplification on fluorescence in situ hybridization (FISH) study
  • previous or current systemic with the exception of curatively treated non-melanoma skin cancer or cervical carcinoma in situ, unless there has been a disease-free interval of at least 5 years
  • Patients who have received prior chemotherapy
  • inadequate hematological function defined as (ANC)less than 1,500/mm3, and less than 100,000/mm3
  • inadequate hepatic function defined as: serum greater than 1.5 times the (ULN) (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULN
  • inadequate renal function defined as serum creatinine greater than 1.5 times the ULN
  • (LVEF) \< 50% confirmed by multiple-gated acquisition (MUGA) scan or echocardiogram
  • concomitant illness that might be aggregated by chemotherapy or interfere study assessment. For examples, active, non- controlled infection (such as and , , infectious tuberculosis) or other active, non-controlled disease such as congestive heart failure, ischemic heart disease, uncontrolled hypertension or arrhythmia, unstable diabetes mellitus, and active peptic ulcer
  • patients who are presence of liver cirrhosis or are HBV/HCV carrier
  • participation in another clinical trial with any drug within 30 days prior to entry
  • pregnant or breast feeding women
  • fertile women of unless using a reliable and appropriate method throughout the treatment period and for three months following cessation of treatment
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
254 participants (estimated)

Study arms

  • Active comparator
    EC

    Cyclophosphamide,600 mg/m2 q3wk and Epirubicin,90 mg/m2 q3wk

    Drug: Epirubicin+Cyclophosphamide

  • Experimental
    LC

    liposomal doxorubicin, 37.5 mg/m2 q3wk, and Cyclophosphamide,600 mg/m2 q3wk

    Drug: liposomal-doxorubicin+Cyclophosphamide

Interventions

  • DrugEpirubicin+Cyclophosphamide

    Drug pages: Epirubicin · Cyclophosphamide

    Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.

  • Drugliposomal-doxorubicin+Cyclophosphamide

    Drug pages: Liposomal doxorubicin · Cyclophosphamide

    Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    To evaluate the disease-free survival (DFS) in the two randomized arms after therapy with LC vs. EC in chemo-naive Her2-patients with stage I or II breast cancer

    Time frame: 5 years

Secondary outcomes

  1. Overall survival

    Time frame: 5 years

  2. Quality of life

    Time frame: Baseline and every 3 weeks during therapy

  3. Safety profiles

    Incidence and severity of adverse event (neutropenia, palmar-plantar erythrodysesthesia, cardiac function, and secondary leukemia) by assessing the toxicities and tolerability

    Time frame: 5 years

  4. Survival correlation with biomarkers expression

    Time frame: At approximately of 5 years maximum FU

07

Study locations

9 sites
  • Changhua Christian Hospital
    Changhua, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung, Taiwan
  • Chang-Gung Memorial Hospital, Linkou
    Linkou, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Shin Kong Wu Ho-Su Memorial Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Oct 2022 and a completion of Oct 2022. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2010
First posted
Sep 28, 2010
Start
Jun 2010
Primary completionEst.
Oct 31, 2022
CompletionEst.
Oct 31, 2022
Last update
Nov 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01210768
Lead sponsor
TTY Biopharm
Responsible party
Sponsor
First posted
Sep 28, 2010
Start date
Jun 2010
Primary completion
Oct 31, 2022 (estimated)
Completion
Oct 31, 2022 (estimated)
Last update
Nov 23, 2021

Study contacts

Ming-Feng Hou, MD
principal investigator · Kaohsiung Medical University Chung-Ho Memorial Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Cyclophosphamide

Start the discussion